Dr. John Cush @RheumNow( View Tweet )
Dr. John Cush @RheumNow( View Tweet )
Links:
Links:
Links:
Links:
Links:
Links:
B-cell targeting has moved to the centre of IgG4-related disease treatment, with inebilizumab, a CD19 depleter, as the recent benchmark. At EULAR 2026, INDIGO tested whether the disease can be controlled by switching B cells off rather than depleting them.
Read Article
Dr. John Cush @RheumNow( View Tweet )
Links:
Janet Pope @Janetbirdope( View Tweet )
Systemic sclerosis is a rare connective tissue disorder characterised by autoimmune features with vascular manifestations, causing fibrosis of the skin and internal organs. EULAR is focused on systemic sclerosis as the rheumatic disease with the highest morbidity and mortality. New data
Read Article
CD19-directed CAR T-cell therapy has rapidly moved into autoimmune disease, driven in large part by striking reports in SLE, where sustained drug-free remission has raised the possibility of a true immune reset. In RA, where multiple effective therapeutic classes already exist, the relevance of
Read Article
Links:
Dr. John Cush @RheumNow( View Tweet )
Jiha Lee @JihaRheum( View Tweet )
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
